Oxaliplatin, Docetaxel, and Radiation Therapy in Treating Patients With Unresectable Stage II/III or Recurrent NSCLC
This study has been terminated.
(Withdrawn due to lack of accrual)
Sponsor:
Masonic Cancer Center, University of Minnesota
Information provided by:
Masonic Cancer Center, University of Minnesota
ClinicalTrials.gov Identifier:
NCT00356941
First received: July 26, 2006
Last updated: January 20, 2010
Last verified: January 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Oxaliplatin and docetaxel may make tumor cells more sensitive to radiation therapy. Giving oxaliplatin and docetaxel together with radiation therapy may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of oxaliplatin when given together with docetaxel and radiation therapy in treating patients with unresectable stage II or stage III or recurrent non-small cell lung cancer .
| Condition | Intervention | Phase |
|---|---|---|
|
Lung Cancer |
Drug: docetaxel Drug: oxaliplatin Procedure: radiation therapy |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase I Study of Oxaliplatin in Combination With Docetaxel and Radiotherapy in Patients With Unresectable or Recurrent Non-Small Cell Lung Cancer (NSCLC) |
Resource links provided by NLM:
Further study details as provided by Masonic Cancer Center, University of Minnesota:
Primary Outcome Measures:
- Maximum tolerated dose of oxaliplatin in combination with docetaxel and radiotherapy [ Time Frame: Within 90 days of radiotherapy ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Dose-limiting toxicities [ Time Frame: Within 90 days of radiotherapy ] [ Designated as safety issue: Yes ]
- Objective tumor response [ Time Frame: Every 3 months up to 24 months ] [ Designated as safety issue: No ]
| Enrollment: | 4 |
| Study Start Date: | April 2006 |
| Study Completion Date: | May 2007 |
| Primary Completion Date: | May 2007 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Chemoradiation Treated Patients
Patients receiving Docetaxel, Oxaliplatin and radiotherapy.
|
Drug: docetaxel
60 mg/m2 on day 1 of each week during radiation therapy
Other Name: Taxotere
Drug: oxaliplatin
Escalating dose per assignment: 20-50 mg/m2 on day 2 of each week during radiation therapy
Other Name: Eloxatin
Procedure: radiation therapy
2 Gy Days 1-5 each week, total dose of 70Gy
Other Name: radiotherapy
|
Detailed Description:
OBJECTIVES:
Primary
- Determine the maximum tolerated dose of oxaliplatin when given with docetaxel and thoracic radiotherapy in patients with unresectable stage II, IIIA, or IIIB or recurrent non-small cell lung cancer.
Secondary
- Determine the dose-limiting toxicities of this regimen in these patients.
- Determine the objective tumor response in patients treated with this regimen.
OUTLINE: This is a dose-escalation study of oxaliplatin.
- Induction therapy: Patients undergo radiotherapy once a day on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, and 43-47. Patients also receive docetaxel intravenous (IV) over 1 hour on days 1, 8, 15, 22, 29, 36, and 43 and oxaliplatin IV over 2-4 hours on days 2, 9, 16, 23, 30, 37, and 44. Patients with stable or responding disease proceed to consolidation therapy.
Cohorts of 6 patients receive escalating doses of oxaliplatin during induction therapy until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 3 of 6 patients experience dose-limiting toxicity.
- Consolidation therapy: Beginning 3 weeks after the completion of induction therapy, patients receive consolidation therapy comprising docetaxel IV over 1 hour immediately followed by oxaliplatin IV over 2-4 hours on day 1. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed at 4 weeks and then every 3 months for up to 2 years.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
Diagnosis of non-small cell lung cancer (NSCLC) meeting 1 of the following criteria:
- Medically inoperable or unresectable stage II, IIIA, or IIIB disease
- Post-resection intrathoracic tumor recurrence
- Measurable disease by computed tomography(CT) scan
- No evidence of small cell histology
- No significant pleural effusion on chest x-ray or malignant pleural effusion on cytology
- No metastatic disease
- Eastern Cooperative Oncology Group (ECOG) (Zubrod) performance status 0-1
- Absolute granulocyte count ≥ 2,000/mm³
- Platelet count ≥ 100,000/mm³
- Hemoglobin ≥ 8.0 g/dL
- Bilirubin ≤ 1.5 mg/dL
- Serum glutamic oxaloacetic transaminase (SGOT) ≤ 1.5 times upper limit of normal (unless abnormality is caused by documented benign disease)
- Creatinine ≤ 1.5 mg/dL
- Weight loss ≤ 10% within the past 3 months
- Forced expiratory volume (FEV) 1 ≥ 1,000 cc
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3 months after completion of study treatment
Exclusion Criteria:
- Synchronous (except for nonmelanomatous skin cancer) or prior invasive malignancy, unless disease free for > 3 years
- Myocardial infarction within the past 6 months
Symptomatic heart disease, including any of the following:
- Angina
- Congestive heart failure
- Uncontrolled arrhythmia
- Active infection or fever ≥ 38.5°C within the past 3 days
- Known hypersensitivity to any of the components of oxaliplatin or docetaxel
- Prior thoracic or neck radiotherapy
- Prior docetaxel or oxaliplatin
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00356941
Locations
| United States, Minnesota | |
| University of Minnesota Cancer Center | |
| Minneapolis, Minnesota, United States, 55455 | |
Sponsors and Collaborators
Masonic Cancer Center, University of Minnesota
Investigators
| Study Chair: | L. Chinsoo Cho, MD | University of Minnesota - Clinical and Translational Science Institute |
More Information
Additional Information:
No publications provided
| Responsible Party: | Chinsoo Cho MD, Masonic Cancer Center, University of Minnesota |
| ClinicalTrials.gov Identifier: | NCT00356941 History of Changes |
| Other Study ID Numbers: | 2005LS073, UMN-0511M77529, UMN-OX-04-007 |
| Study First Received: | July 26, 2006 |
| Last Updated: | January 20, 2010 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Masonic Cancer Center, University of Minnesota:
|
recurrent non-small cell lung cancer stage II non-small cell lung cancer stage IIIA non-small cell lung cancer stage IIIB non-small cell lung cancer |
Additional relevant MeSH terms:
|
Carcinoma, Non-Small-Cell Lung Lung Neoplasms Carcinoma, Bronchogenic Bronchial Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms |
Lung Diseases Respiratory Tract Diseases Oxaliplatin Docetaxel Antineoplastic Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 23, 2013